Of note, co-treatment with chloroquine also partially rescued the effects of this multikinase inhibitor on the emergence of EGFR-TKI-resistant cells (Fig. 4G), implying that its ability to induce EGFR down-regulation contributes to the mechanism of action of sorafenib in NSCLC cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.